Quantified tumor T1 is a generic early-response imaging biomarker for chemotherapy reflecting cell viability

Clinical Cancer Research

Volumn 16, Issue 1, 2010, Pages 212-225

  McSheehy, Paul M J ^a   Weidensteiner, Claudia ^a   Cannet, Catherine ^a   Ferretti, Stephane ^a   Laurent, Didier ^a   Ruetz, Stephan ^a   Stumm, Michael ^a   Allegrini, Peter R ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; BIOLOGICAL MARKER; CHOLINE; EPOTHILONE B; EVEROLIMUS; FLUOROURACIL; KI 67 ANTIGEN; PACLITAXEL; PROTON; UNCLASSIFIED DRUG; VATALANIB; WATER; WATER PROTON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DOSE RESPONSE; DRUG EFFICACY; EX VIVO STUDY; FEMALE; FIBROSARCOMA; HISTOLOGY; HUMAN; HUMAN CELL; MOUSE; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SINGLE DRUG DOSE; TISSUE NECROSIS; TISSUE PRESSURE; TREATMENT RESPONSE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED STRAINS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; RATS; RATS, INBRED BN;

EID: 74949119335     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0686     Document Type: Article

References (48)

1. Tanaka C, O'Reilly T, Kovarik JM, et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008;26:1596-602.
2. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
3. Vermorken JB, Parmar MKB, Brady MF, et al. Clinical trials in ovarian carcinoma: study methodology. Ann Oncology 2005;16:20-9.
4. Abramovitz M, Leyland-Jones B. Application of array-based genomic and epigenomic technologies to unraveling the heterogeneous nature of breast tumors: on the road to individualized treatment. Cancer Genomics Proteomics 2007;4:135-45.
5. Stephan RM, Gillies RJ. Promise and progress for functional and molecular imaging of response to targeted therapies. Pharm Res 2007;24:1172-85.
6. Mankoff DA, Eary JF, Link JM, et al. Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond. Clin Cancer Res 2007;13:3460-9.
7. Van Laarhoven HWM, Punt CJA, Kamm YJL, Heerschap A. Monitoring fluoropyrimidine metabolism in solid tumors with in vivo 19F magnetic resonance spectroscopy. Crit Rev Oncol Hematol 2005;56:321-43.
8. Jain RK. Barrier to drug delivery in solid tumors. Sci Am 1994;271:58-65.
9. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7.
10. Milosevic M, Fyles A, Hedley D, et al. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res 2001;61:6400-5.
11. Flaherty KT, Rosen MA, Heitjan DF, et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 2008;7:496-50.
12. McSheehy P, Allegrini P, Ametaby S, et al. Minimally invasive biomarkers for therapy monitoring. Ernst Schering Found Symp Proc 2008;4:153-88.
13. Weidensteiner C, Rausch M, McSheehy PM, Allegrini PR. Quantitative dynamic contrast-enhanced MRI in tumor-bearing rats and mice with inversion recovery TrueFISP and two contrast agents at 4.7 T. J Magn Reson Imaging 2006;24:646-56.
14. Braunschweiger PG, Schiffer LM, Furmanski P. The measurement of extracellular water volumes in tissues by gadolinium modification of 1H-NMR spin lattice (T1) relaxation. Magn Reson Imaging 1986;4:285-91.
15. Braunschweiger PG, Schiffer LM, Furmanski P. 1H-NMR relaxation times and water compartmentalization in experimental tumor models. Magn Reson Imaging 1986;4:335-42.
16. Jakobsen I, Kaalhus O, Lyng H, Rofstad EK. Detection of necrosis in human tumour xenografts by proton magnetic resonance imaging. Br J Cancer 1995;71:456-61.
17. Gambarota G, Veltien A, van Laarhoven H, et al. Measurements of T1 and T2 relaxation times of colon cancer metastases in rat liver at 7 T. Magn Res Mat Phys Biol Med 2004;17:281-7.
18. Rofstad EK, Steinsland E, Kaalhus O, et al. Magnetic resonance imaging of human melanoma xenografts in vivo: proton spin-lattice and spin-spin relaxation times versus fractional tumour water content and fraction of necrotic tumour tissue. Int J Radiat Biol 1994;65:387-401.
19. Jakobsen I, Lyng H, Kaalhus O, Rofstad EK. MRI of human tumor xenografts in vivo: proton relaxation times and extracellular tumor volume. Magn Reson Imaging 1995;13:693-700.
20. Lyng H, Tufto I, Skretting A, Rofstad EK. Proton relaxation times and interstitial fluid pressure in human melanoma xenografts. Br J Cancer 1997;75:180-3.
21. Olsen G, Lyng H, Tufto I, et al. Measurement of proliferation activity in human melanoma xenografts by magnetic resonance imaging. Magn Reson Imaging 1999;17:393-402.
22. Le Moyec L, Pellen P, Merdrignac-Le N, et al. Proton NMR relaxation times of experimental Lewis lung carcinoma after irradiation. Radiother Oncol 1988;13:1-8.
23. Chenevert TL, McKeever PE, Ross BD. Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res 1997;3:1457-66.
24. Duvvuri U, Poptani H, Feldman M, et al. Quantitative T1rho magnetic resonance imaging of RIF-1 tumors in vivo: detection of early response to cyclophosphamide therapy. Cancer Res 2001;61:7747-53.
25. Kroeker RM, Stewart CA, Bronskill MJ, Henkelman RM. Continuous distributions of NMR relaxation times applied to tumors before and after therapy with X-rays and cyclophosphamide. Magn Reson Med 1988;6:24-36.
26. Thomsen C, Sørensen PG, Karle H, Christoffersen P, Henriksen O. Prolonged bone marrow T1-relaxation in acute leukaemia. In vivo tissue characterization by magnetic resonance imaging. Magn Reson Imag 1987;5:251-7.
27. Jensen KE, Sørensen PG, Thomsen C, et al. Magnetic resonance imaging of the bone marrow in patients with acute leukemia during and after chemotherapy. Acta Radiologica 1990;31:361-9.
28. Santoni R, Bucciolini M, Chiostrini C, Cionini L, Renzi R. Quantitative magnetic resonance imaging in cervical carcinoma: a report on 30 cases. Br J Radiol 1991;64:498-504.
29. Smith SR, Roberts N, Percy DF, Edwards RH. Detection of bone marrow abnormalities in patients with Hodgkin's disease by T1 mapping of MR images of lumbar vertebral bone marrow. Br J Cancer 1992;65:246-51.
30. 18F]-tracers in various experimental tumour models by PET imaging and identification of an early response biomarker for the novel microtubule stabiliser patupilone. Mol Imaging Biol 2009;11:308-21.
31. Ferretti S, Allegrini PR, O'Reilly T, et al. Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure. Clin Cancer Res 2005;11:7773-84.
32. O'Reilly T, Wartmann M, Brueggen J, et al. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo. Cancer Chemother Pharmacol 2008;62:1045-54.
33. He L, Yang CP, Horwitz SB. Mutations in β-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines. Mol Cancer Ther 2001;1:3-10.
34. Nekolla S, Gneiting T, Syha J, et al. T1 maps by K-space reduced snapshot-FLASH MRI. J Comput Assist Tomogr 1992;16:327-32.
35. Schmitt P, Griswold MA, Jakob PM, et al. Inversion recovery True-FISP: quantification of T(1), T(2), and spin density. Magn Reson Med 2004;51:661-7.
36. Troprés I, Grimault S, Vaeth A, et al. Vessel size imaging. Magn Reson Med 2001;45:397-408.
37. Gruetter R. Automatic, localized in vivo adjustment of all first- and second-order shim coils. Magn Res Med 1993;29:804-11.
38. 1H MR spectroscopy. Magn Res Med 2003;50:1134-43.
39. Lane HA, Wood JM, McSheehy PM, et al. The mTOR inhibitor RAD001 (everolimus) has anti-angiogenic/vascular properties distinct from a VEGF-R tyrosine kinase inhibitor. Clin Cancer Res 2008;15:1612-22.
40. Klein CL, Wagner M, Kirkpatrick CJ, et al. A new quantitative test method for cell proliferation based on detection of the Ki67 protein. J Mater Sci Mater Med 2000;11:125-32.
41. Curran-Everett D. Multiple comparisons: philosophies and illustrations. Am J Physiol Regulatory Integrative Comp Physiol 2000;279:R1-8.
42. Ferretti S, Allegrini PR, Becquet M, McSheehy PM. Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics. Neoplasia 2009;11:874-81.
43. 2 modulation by oxygen and carbogen. Magn Reson Med 2009;61:75-83.
44. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605-12.
45. Spaepen K, Stroobants S, Dupont P, et al. [(18)F]FDG PET monitoring of tumour response to chemotherapy: Does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 2003;30:682-8.
46. Symms M, Jäger HR, Schmierer K, Yousry TA. A review of structural magnetic resonance neuroimaging. J Neurology, Neurosurgery & Psychiatry 2004;75:1235-44.
47. Landberg G, Tan EM, Roos G. Flow cytometric multiparameter analysis of proliferating cell nuclear antigen/cyclin and Ki-67 antigen: a new view of the cell cycle. Exp Cell Res 1990;187:111-8.
48. Beresford MJ, Wilson GD, Makris A. Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res 2006;8:216-27.